FDA trial shows sustained effect for Ozurdex on diabetic

The dexamethasone intraocular implant OZURDEX® (Allergan)

can bring about significant and visual improvement in patients

with diabetic macular oedema, with generally only transient

increases in IOP but with a high incidence of cataract in

phakic patients, said EURETINA president ,Francesco

Bandello MD, told attendees at an EURETINA free paper

session

He reported the pooled results of two FDA studies conducted

by the MEAD study group involving a total of 1048 patients

with diabetic macular oedema. The patients were randomised

into three groups to receive Ozurdex at a dosage of 0.7 mg or

0.35 mg , or sham treatment, with repeated injections when

indicated at intervals no shorter than six months.

Professional and personal goals drive practice ownership and operational choices.

Improving access through financially and environmentally sustainable innovation.

New ideas and industry, colleague, and funding contacts among the benefits.

Partnerships with academia and industry promote innovation.

Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.

Surgeons may prefer some IOLs for their patients, but what about for themselves?

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Helping young surgeons build confidence and expertise.